CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg developed by Novo Nordisk. The REDEFINE phase 3 program reported topline data in March 2025, and the regulatory submission to the FDA is expected by late 2026, with potential approval in 2027. The clinical question CagriSema tries to answer is whether adding a long-acting amylin analogue restores the weight loss ceiling that GLP-1 monotherapy hits at around 15% of body weight.<\/p>\n
The current evidence suggests it does, partially. REDEFINE 1 produced 22.7% mean weight loss in adults with obesity, sitting between Wegovy\u00ae (14.9% in STEP 1, Wilding et al. 2021 NEJM) and Zepbound\u00ae (20.9% in SURMOUNT-1, Jastreboff et al. 2022 NEJM). The diabetes arm and cardiovascular outcomes trial are still maturing, and several adjacent indications (liver disease, sleep apnea, alcohol use disorder) are in early-stage exploration.<\/p>\n
This article covers what’\\”s settled, what’\\”s still in trial, and what’\\”s realistic to expect from CagriSema over the next 24 to 36 months.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
REDEFINE 1 enrolled 3,417 adults with BMI 30+ (or 27+ with one comorbidity) across 11 countries.<\/strong> Participants received weekly subcutaneous CagriSema versus placebo, semaglutide 2.4 mg monotherapy, and cagrilintide 2.4 mg monotherapy across the trial arms. The primary endpoint was percent change in body weight at 68 weeks.<\/p>\n Quick Answer: REDEFINE 1: 22.7% mean weight loss at 68 weeks in adults with obesity (n=3,417)<\/p>\n Topline results from the Novo Nordisk March 2025 release: CagriSema produced 22.7% mean weight loss versus 3.0% with placebo. Semaglutide monotherapy in the same trial produced 16.1%, and cagrilintide alone produced 11.8%. The combination beat both monotherapies, confirming the dual-mechanism hypothesis.<\/p>\n The proportion of participants losing 20% or more of body weight was 56% with CagriSema, versus 22% with semaglutide alone. This is the number that most strongly signals CagriSema may shift the obesity treatment ceiling.<\/p>\n Trial duration matters. Most STEP and SURMOUNT trials run 68 to 72 weeks, the standard for chronic weight management drug approval. Longer-term data (3 to 5 years) doesn’\\”t exist yet for CagriSema, so durability assumptions are extrapolated from semaglutide.<\/p>\n REDEFINE 2 enrolled 1,206 adults with type 2 diabetes (mean A1c 8.4%) and obesity.<\/strong> Topline results showed CagriSema produced 13.7% weight loss at 68 weeks versus placebo, with concurrent A1c reduction approaching SURPASS-level results.<\/p>\n The weight loss in diabetic patients was lower than in REDEFINE 1, consistent with the well-documented pattern that diabetes blunts GLP-1 weight response. SURMOUNT-2 (Garvey et al. 2023 Lancet) showed tirzepatide produced 15.7% weight loss in diabetic patients versus 20.9% in non-diabetic patients (SURMOUNT-1).<\/p>\n The A1c data was the key win. Most diabetic patients reached A1c under 7% on CagriSema, and a substantial fraction achieved A1c under 6.5% (the ADA-defined threshold for diabetes remission). REDEFINE 2 wasn’\\”t powered to assess remission specifically, but the magnitude of A1c reduction suggests CagriSema may compete with tirzepatide as a first-line option for obesity-driven type 2 diabetes.<\/p>\n REDEFINE 3 is the cardiovascular outcomes trial (CVOT) enrolling approximately 7,000 adults with established cardiovascular disease and overweight or obesity.<\/strong> The primary endpoint is three-point MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Trial completion is projected for late 2026 or early 2027.<\/p>\n The SELECT trial (Lincoff et al. 2023 NEJM) already established that semaglutide 2.4 mg reduces MACE by 20% in non-diabetic patients with overweight or obesity and CVD. If REDEFINE 3 shows similar or better MACE reduction, CagriSema would launch with a cardiovascular indication out of the gate, which most chronic weight management drugs don’\\”t have.<\/p>\n The mechanistic question is whether adding cagrilintide adds cardiovascular benefit beyond the semaglutide signal. Amylin has its own cardiometabolic effects (improved lipid profile, reduced ectopic fat) but no large CV outcome trial has tested amylin monotherapy.<\/p>\n Yes. The MASH (metabolic dysfunction-associated steatohepatitis) space is increasingly crowded. Semaglutide alone showed liver benefit in the ESSENCE phase 3 trial reported in late 2024, with significant reductions in liver fat and inflammation in patients with MASH. Tirzepatide showed similar effects in SYNERGY-NASH phase 2 (Loomba et al. 2024 NEJM).<\/p>\n CagriSema is being studied in a phase 2 MASH trial separately from REDEFINE. Early results aren’\\”t yet public. The hypothesis is that the combination of GLP-1 + amylin produces deeper weight loss and better insulin sensitization, both of which drive MASH improvement. Resmetirom (Madrigal’\\”s thyroid hormone receptor beta agonist) is already FDA-approved for MASH based on MAESTRO-NASH (Harrison et al. 2024 NEJM), so any GLP-1-based MASH drug will be compared to that benchmark.<\/p>\n If CagriSema clears phase 3 in MASH, it could become a dual-purpose drug for obese patients with concurrent liver disease, which describes a large fraction of the obesity population.<\/p>\n SURMOUNT-OSA led to tirzepatide’\\”s FDA approval for moderate-to-severe OSA in December 2024, the first weight-loss drug ever approved for sleep apnea.<\/strong> CagriSema hasn’\\”t announced a dedicated OSA trial yet, but the same mechanism should apply because OSA improvement on GLP-1s correlates with weight loss magnitude. A CagriSema OSA indication would be a phase 4 expansion rather than a launch indication.<\/p>\n Heart failure with preserved ejection fraction (HFpEF) is another space. STEP-HFpEF (Kosiborod et al. 2023 NEJM) showed semaglutide improved symptoms and exercise capacity in obese HFpEF patients. CagriSema would likely produce similar or greater benefit but hasn’\\”t been formally studied in HFpEF.<\/p>\n Chronic kidney disease is open. FLOW (Perkovic et al. 2024 NEJM) showed semaglutide reduced kidney and cardiovascular death by 24% in diabetic CKD patients. Whether the combination drug adds renal benefit is untested.<\/p>\n Alcohol use disorder is being explored academically. Several small studies have shown semaglutide reduces alcohol consumption. CagriSema is part of this exploration but no large trial has launched.<\/p>\n Cagrilintide is a long-acting amylin analogue.<\/strong> Native amylin is a hormone co-secreted with insulin by pancreatic beta cells and acts on the area postrema to slow gastric emptying and reduce food intake. The problem with native amylin is its very short half-life (about 13 minutes) and its tendency to aggregate, which limits therapeutic use.<\/p>\n Cagrilintide is engineered for stability and a half-life of about 7 days, enabling weekly dosing. In a phase 2 trial (Lau et al. 2021 Lancet), cagrilintide 4.5 mg weekly produced 10.8% weight loss at 26 weeks in adults with obesity, versus 3.0% with placebo. That’\\”s essentially what liraglutide does at the same time point, achieved with weekly rather than daily dosing.<\/p>\n The phase 2 trial also showed cagrilintide and semaglutide produced additive weight loss when combined, supporting the dual-mechanism approach behind CagriSema. The dose used in CagriSema (2.4 mg cagrilintide) is lower than the 4.5 mg phase 2 dose to balance efficacy and tolerability in the combined formulation.<\/p>\n Gastrointestinal symptoms dominate.<\/strong> Nausea affected approximately 50% of CagriSema patients during titration, vomiting affected 16 to 19%, diarrhea around 20%, and constipation around 15%. Most events were mild to moderate and concentrated in weeks 4 to 12 of titration. Serious adverse events were rare and similar across arms.<\/p>\n The discontinuation rate due to adverse events was approximately 6% for CagriSema, compared to roughly 7% for semaglutide alone in STEP 1 and 6% in SURMOUNT-1. The amylin component didn’\\”t produce a meaningful increase in discontinuation despite the higher symptomatic GI burden.<\/p>\n Hypoglycemia was rare in non-diabetic patients. In REDEFINE 2 (diabetic cohort), hypoglycemia occurred in about 10% but mostly in patients also on insulin or sulfonylureas, who required dose adjustments.<\/p>\n No new safety signals emerged that weren’\\”t already documented for semaglutide. The FDA boxed warning for medullary thyroid carcinoma will carry over from the semaglutide label.<\/p>\n Key Takeaway: Cagrilintide alone produced 10.8% weight loss in phase 2 (Lau et al. 2021 Lancet)<\/p>\n Novo Nordisk submitted CagriSema data to regulatory authorities through 2025 and 2026.<\/strong> The FDA standard review timeline is 10 months from acceptance, though priority review could shorten this to 6 months if granted. Realistic approval window: late 2026 to mid-2027.<\/p>\n Pricing is unknown but expected to align with current GLP-1 list prices. Wegovy lists around 1,350 dollars per month, Zepbound around 1,060. CagriSema will likely launch in the same range. Insurance coverage for obesity drugs remains limited in commercial plans and absent in Medicare for obesity indications.<\/p>\n Compounded versions face a different timeline. Cagrilintide isn’\\”t currently available for compounding because there’\\”s no approved branded product yet, and the FDA’\\”s compounding rules typically require an approved drug shortage or specific clinical need. Whether compounded CagriSema becomes available depends on shortage declarations after launch and FDA enforcement priorities.<\/p>\n It signals the end of single-mechanism GLP-1 dominance.<\/strong> CagriSema, tirzepatide (dual GIP\/GLP-1), retatrutide (triple GIP\/GLP-1\/glucagon, phase 3), orforglipron (oral GLP-1), and several earlier-stage candidates (amylin-only, glucagon-only, leptin sensitizers) all represent moves beyond GLP-1 monotherapy.<\/p>\n The pattern across these candidates is a higher efficacy ceiling, more 20-plus percent responders, and a willingness to accept slightly worse short-term tolerability for better long-term weight loss. Retatrutide in particular showed 24.2% mean weight loss in phase 2 (Jastreboff et al. 2023 NEJM), suggesting the next ceiling is closer to bariatric surgery outcomes (25 to 30%).<\/p>\n For patients, the practical implication is that the drug shopping list is going to keep expanding through 2028. The right drug for a given patient will increasingly depend on side effect profile, comorbidities, and cost rather than efficacy alone, because most of these new agents will get into the 20-plus percent weight loss range.<\/p>\n TrimRx patients exploring options can take the free assessment quiz to see what’\\”s clinically appropriate today, and the personalized treatment plan adjusts as new drugs become available.<\/p>\n Discontinuation due to adverse events ran approximately 6% across the CagriSema arms in REDEFINE 1.<\/strong> STEP 1 showed semaglutide discontinuation at about 7%. SURMOUNT-1 showed tirzepatide discontinuation at 6%. Across the class, the consistent finding is that roughly 5 to 8% of patients can’\\”t tolerate the medication regardless of titration strategy.<\/p>\n Real-world discontinuation in routine practice is dramatically higher than in trials. Insurance claims analyses suggest 50 to 70% of patients starting semaglutide discontinue within 12 months for a combination of side effects, cost, supply issues, and lack of perceived progress. Whether CagriSema will follow this same real-world drop-off depends heavily on coverage, cost, and patient education.<\/p>\n Trial patients have unusually strong support: dedicated study coordinators, free medication, regular check-ins, and clear titration protocols. Replicating this in real-world care is the operational challenge for TrimRx and similar telehealth platforms, where the clinician contact frequency and titration guidance directly affect how many patients reach maintenance dose successfully.<\/p>\n Amylin and GLP-1 are both gut-brain peptides but they act on different brain circuits.<\/strong> GLP-1 receptors are dense in the arcuate nucleus and the area postrema. Amylin receptors are concentrated in the area postrema and adjacent dorsal vagal complex. The overlap drives the additive nausea, the divergence drives the additive weight loss.<\/p>\n Cagrilintide also affects food reward processing differently from semaglutide. Functional MRI studies of amylin agonism show stronger suppression of palatable food reward responses (sweet, fatty foods specifically) than GLP-1 monotherapy. This may explain why some REDEFINE 1 patients reported losing interest in foods that had previously been hard to resist.<\/p>\n Gastric emptying suppression is the third mechanism. Both semaglutide and cagrilintide slow emptying, but at different times in the gastric cycle. The combination produces more consistent slowing across the digestion period, which translates to longer-lasting satiety after meals.<\/p>\n The clinical implication is that CagriSema may work better than monotherapy for specific patient subgroups: those with high palatability-driven eating, those with rapid gastric emptying at baseline, and those who hit a plateau on semaglutide despite full-dose adherence.<\/p>\n Durability beyond 2 years isn’\\”t known.<\/strong> The STEP 5 extension showed semaglutide maintained 15.2% weight loss at 104 weeks (Garvey et al. 2022 Nature Medicine), but most patients regain when treatment stops. Whether CagriSema produces equivalent or better durability remains to be seen.<\/p>\n Lean mass preservation is increasingly important. GLP-1 weight loss is roughly 30 to 40% lean mass, which is similar to non-pharmacologic weight loss but troubles many clinicians because of long-term sarcopenia concerns. Whether CagriSema’\\”s amylin component changes this ratio is not yet published.<\/p>\n Bone health on GLP-1s is understudied. Some early observational data suggests fracture risk may rise with substantial weight loss, similar to bariatric surgery outcomes. Long-term DEXA scan data from REDEFINE participants would help clarify whether bone density loss accompanies weight loss on CagriSema.<\/p>\n Pediatric safety and efficacy data don’\\”t exist. Adolescents with severe obesity are a growing population and would benefit from effective pharmacotherapy. CagriSema’\\”s adolescent trials likely follow several years after adult approval.<\/p>\n Bottom line: Probable label indications at launch: chronic weight management and type 2 diabetes<\/p>\n Novo Nordisk released topline results via press release in March 2025. Full peer-reviewed publication in NEJM or Lancet is expected in 2026 or 2027. ClinicalTrials.gov has the registered protocols (NCT05567796 for REDEFINE 1).<\/p>\n Yes. The area postrema is the brain’\\”s vomiting trigger zone, and both amylin and GLP-1 activate it. Stacking the two amplifies the early nausea response. Slow titration is the standard mitigation.<\/p>\n Likely yes, but several years after adult approval. STEP TEENS (Kelly et al. 2022 NEJM) established the regulatory pathway for adolescent semaglutide. Expect a similar adolescent CagriSema trial to launch in 2027 or later.<\/p>\n REDEFINE 1 didn’\\”t formally measure food preference changes, but observational data from semaglutide users consistently shows reduced cravings for sweet and high-fat foods. The amylin addition may strengthen this effect based on rodent studies, though human data is preliminary.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg developed by Novo Nordisk.<\/p>\n","protected":false},"author":11,"featured_media":92633,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"CagriSema Latest Research: New Indications, Trials & What'\\''s Coming","_yoast_wpseo_metadesc":"CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg developed by Novo Nordisk.","_yoast_wpseo_focuskw":"cagrisema latest research","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[20,41],"class_list":["post-89209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-cagrisema","tag-research"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89209"}],"version-history":[{"count":4,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89209\/revisions"}],"predecessor-version":[{"id":93634,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89209\/revisions\/93634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92633"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Did REDEFINE 2 Find in Type 2 Diabetes?<\/h2>\n
What About Cardiovascular Outcomes From REDEFINE 3?<\/h2>\n
Is CagriSema Being Studied for Liver Disease?<\/h2>\n
What About Obstructive Sleep Apnea and Other Indications?<\/h2>\n
How Does Cagrilintide Alone Work, and What Did Its Phase 2 Trial Show?<\/h2>\n
What Is the Side Effect Profile From REDEFINE 1?<\/h2>\n
What’\\”s the Timeline for FDA Approval?<\/h2>\n
What Does CagriSema Mean for the Obesity Drug Pipeline Overall?<\/h2>\n
How Do the REDEFINE Trial Discontinuation Patterns Compare to Other GLP-1 Trials?<\/h2>\n
What Does the Cagrilintide Mechanism Contribute That GLP-1 Alone Doesn’\\”t?<\/h2>\n
What Are the Most Important Open Questions for CagriSema Research?<\/h2>\n
FAQ<\/h2>\n
Where Can I Find Published REDEFINE Results?<\/h3>\n
Is the Amylin Component the Reason for Worse Early Nausea?<\/h3>\n
Will CagriSema Be Tested in Adolescents?<\/h3>\n
How Does CagriSema Affect Food Preferences During Weight Loss?<\/h3>\n
Related Articles<\/h2>\n
\n